

HHS Public Access

Author manuscript *J Med Chem.* Author manuscript; available in PMC 2021 February 16.

Published in final edited form as:

J Med Chem. 2020 November 12; 63(21): 12799–12813. doi:10.1021/acs.jmedchem.0c01178.

Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain

Jonathan T. Lloyd,

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Kyle McLaughlin,

Department of Biomedical and Health Sciences, University of Vermont, Burlington, Vermont 05405, United States

Mulu Y. Lubula,

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Jamie C. Gay,

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Andrea Dest,

Department of Biomedical and Health Sciences, University of Vermont, Burlington, Vermont 05405, United States

Cong Gao,

Department of Biomedical and Health Sciences, University of Vermont, Burlington, Vermont 05405, United States

Margaret Phillips,

Supporting Information

- The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01178. Histone peptide and compound C-38 purity/identification data (PDF) Information on the histone peptides used for the dCypher assay (Resource Table A) (XLSX)
- dCypher ATAD2A analysis (Table S1) (XLSX)

Accession Codes

Corresponding Author: Karen C. Glass – *Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States;* Phone: 802-735-2636; karen.glass@acphs.edu; Fax: 802-654-0716. Author Contributions

K.C.G., S.F., J.T.L., and M.P. conceived and designed the experiments. M.R.M. and M.-C.K. performed the dCypher array and analyzed the data. J.T.L., M.Y.L., J.C.G., M.P., S.P.B., C.M.E., and S.C. performed the in vitro biochemical experiments with recombinant proteins and analyzed data. M.T. and G.C. collected the NMR data, and M.P. and K.C.G. analyzed the data. K.C.G. solved the crystal structure. K.M., A.D., C.G., and S.F. carried out the genomic analysis, PCR, and cellular analysis of the ATAD2B splice variant. All authors contributed to the writing of the manuscript, reviewed the results, and approved the final version of the manuscript.

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.jmedchem.0c01178

dCypher ATAD2B analysis (Table S2) (XLSX)

Molecular-string file for the C-38 compound (CSV)

The crystal structure of the ATAD2B bromodomain in complex with C-38 has been deposited in the Protein Data Bank (PDB ID: 6VEO). The authors will release the atomic coordinates upon article publication.

The authors declare the following competing financial interest(s): EpiCypher (M.R.M. and M.-C.K.) is a commercial developer of the dCypher peptide-binding platform used in this study.

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Marco Tonelli,

National Magnetic Resonance Facility at Madison and Department of Biochemistry, University of Wisconsin—Madison, Madison, Wisconsin 53706, United States

Gabriel Cornilescu,

National Magnetic Resonance Facility at Madison and Department of Biochemistry, University of Wisconsin—Madison, Madison, Wisconsin 53706, United States

Matthew R. Marunde,

EpiCypher Inc., Durham, North Carolina 27709, United States

Chiara M. Evans,

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Samuel P. Boyson,

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Samuel Carlson,

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Michael-Christopher Keogh,

EpiCypher Inc., Durham, North Carolina 27709, United States

John L. Markley,

National Magnetic Resonance Facility at Madison and Department of Biochemistry, University of Wisconsin—Madison, Madison, Wisconsin 53706, United States

Seth Frietze,

Department of Biomedical and Health Sciences, University of Vermont, Burlington, Vermont 05405, United States


Karen C. Glass

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, Vermont 05446, United States

Abstract

Bromodomains exhibit preferences for specific patterns of post-translational modifications on core and variant histone proteins. We examined the ligand specificity of the ATAD2B bromodomain and compared it to its closely related paralogue in ATAD2. We show that the ATAD2B bromodomain recognizes mono- and diacetyllysine modifications on histones H4 and H2A. A structure–function approach was used to identify key residues in the acetyllysine-binding pocket that dictate the molecular recognition process, and we examined the binding of an ATAD2 bromodomain inhibitor by ATAD2B. Our analysis demonstrated that critical contacts required for bromodomain inhibitor coordination are conserved between the ATAD2/B bromodomains, with many residues playing a dual role in acetyllysine recognition. We further characterized an alternative splice variant of ATAD2B that results in a loss of function. Our results outline the structural and functional features of the ATAD2B bromodomain and identify a novel mechanism regulating the interaction of the ATAD2B protein with chromatin.

Graphical Abstract



INTRODUCTION

Post-translational modifications (PTMs) on histone proteins play a central role in the regulation of chromatin structure. Lysine acetylation (Kac) is a major PTM widely studied in the establishment of cell-type-specific enhancer patterns. Although largely associated with the opening of chromatin structure and activation of gene transcription,^{1–3} recent studies have found that specific Kac histone marks regulate chromatin compaction and DNA damage response.^{4,5} Altered histone acetylation patterns have been linked to disease progression, which may arise due to the deregulation of enzymes responsible for adding or removing Kac marks, or through the protein interaction modules that recognize and interpret Kac.

Bromodomains are evolutionarily conserved protein–protein interaction modules that serve as Kac epigenetic reader domains. Bromodomain-containing proteins interact with transcription factors and chromatin-modifying complexes and have been reported to participate in epigenetic memory.⁶ In humans, there are 61 known bromodomains found in 46 different proteins.⁷ These bromodomains are divided into eight subfamilies (I–VIII) based on sequence and structural features.⁷ Most families contain a canonical bromodomain

that exhibits binding preference for different histone Kac ligands on core and variant histone proteins. However, atypical bromodomains, such as the TRIM28/KAP1 bromodomain in family VI, lack essential acetyllysine recognition residues and display little to no affinity toward Kac-containing histone peptides.⁷ These noncanonical bromodomains may serve to recognize alternative histone PTMs,^{7,8} or they may interact with acetylation marks found on nonhistone proteins.⁹ Interestingly, some bromodomains, including the family IV bromodomains in BRD7/9, can accommodate larger acyl groups in their binding pockets and have been shown to recognize butyrylated and crotonylated lysine.¹⁰

The Kac-binding activity of the family IV bromodomain-containing proteins, which include the bromodomain-containing proteins ATAD2, ATAD2B, BRPF1, BRD1, BRPF3, BRD7, and BRD9, has been at least partially characterized using high-throughput histone peptide arrays and biochemical and biophysical approaches (Lloyd et.al.).¹¹ The family IV bromodomains recognize mono- and diacetylated lysine residues on histones H2A, H3, and H4. Notably, there is currently no ligand information available for the ATPase family, AAA⁺ domain-containing protein 2B (ATAD2B, also known as KIAA1240). ATAD2B is a nuclear protein that contains two conserved domains: an AAA⁺ ATPase domain and a bromodomain.¹² The AAA⁺ or "ATPases associated with diverse cellular activities" domain is found in a large superfamily of proteins that typically form a hexameric complex, able to recognize ATP to drive molecular remodeling reactions.¹³ The C-terminal bromodomain of ATAD2B is highly homologous to the ATAD2 bromodomain, with a 74.7% sequence identity and 94.4% amino acid similarity.¹ The ATAD2 bromodomain binds to acetylated histones at H4K5ac and H4K12ac, and X-ray crystal structures have elucidated essential features of the binding pocket important for the ligand coordination.^{14,15} Recently, the ATAD2 bromodomain was shown to recognize diacetylated histones, and it associates with H4K5acK12ac modifications found on newly synthesized histones following DNA replication.¹⁶ However, the acetylated histone ligands of the ATAD2B bromodomain are yet to be determined, and the molecular mechanism(s) underlying acetyllysine recognition is currently unclear.

We hypothesized that the ATAD2B bromodomain is likely involved in the recognition of diacetyllysine modifications on the histone tail, similar to its ATAD2 paralogue.¹⁶ To outline the function of the ATAD2B bromodomain, we used a newly developed peptide array technology to screen against a large number of acetylated histone tail peptides and characterized their binding affinity and specificity determinants with a combination of isothermal titration calorimetry (ITC) and nuclear magnetic resonance (NMR) experiments. We determined that the ATAD2B bromodomain recognizes acetylated lysine residues on the N-terminal tails of histones H4 and H2A. ITC was used to characterize the binding affinities of the ATAD2B bromodomain with histone peptide ligands, and we found that the histone H4K5ac (1-15) ligand was the strongest binder. Since the molecular details of acetyllysine recognition have not been determined, we used NMR chemical shift perturbation (CSP) data to map out the Kac-binding pocket on the apo ATAD2B bromodomain structure (Protein Data Bank (PDB) ID: 3LXJ). This allowed us to identify the amino acid residues lying within and outside of the canonical Kac-binding site that are affected by the addition of the acetyllysine ligands. Site-directed mutagenesis coupled with ITC experiments confirmed the role of residues within the bromodomain-binding pocket in ligand coordination. X-ray

crystallography was used to solve the structure of the ATAD2B bromodomain in complex with compound 38, an ATAD2 bromodomain inhibitor developed by GlaxoSmithK-line.¹⁷ From this structure, we identified the molecular contacts important for inhibitor coordination that are conserved between the ATAD2/B bromodomains, many of which are also involved in Kac recognition. Our research supports a model whereby inherent flexibility in the ATAD2/B bromodomain-binding pocket. Notably, we describe a novel ATAD2B bromodomain isoform that lacks the ZA loop in the bromodomain Kac-binding pocket that completely abrogates binding to both inhibitors and histone ligands. Interestingly, this splice variant is not observed in the ATAD2 bromodomain. Our results establish key differences between the ATAD2/B bromodomains, suggesting that these proteins carry out divergent functions within the cell. These data advance our understanding of how the ATAD2B bromodomain recognizes and selects specific Kac modifications, and provides new information that will inform the design of small-molecule compounds to specifically target the ATAD2/B bromodomains.

RESULTS

ATAD2B Bromodomain Recognizes Mono- and Diacetylated Histones.

Bromodomains are known as Kac reader domains;¹⁸ however, the histone ligands of the ATAD2B bromodomain are yet to be determined. To identify the Kac modifications recognized by the ATAD2B bromodomain, we used a combination of peptide array, NMR, and ITC methods. We first used the dCypher platform to screen the recombinant ATAD2 and ATAD2B bromodomains against 288 histone peptides (containing single or combinatorial PTMs) after determining the optimal protein concentrations (Figure S1A,B). The PTMs tested included lysine methylation (me1-2-3), arginine methylation (me1-2a-2s), lysine acylation (acetyl, butyryl, crotonyl, propionyl), and phosphorylation (on S/T/Y). The ATAD2B bromodomain bound to 39 PTM peptide ligands from histores H4, H2A and the histone variant H2A.X (Figure 1A,B), predominantly recognizing acetyllysine modifications but permissive for adjacent PTMs (e.g., methylation, phosphorylation) or alternate shortchain acylations (propionylation and butyrylation). In comparison, the ATAD2 bromodomain appears to recognize a more limited subset of histone ligands, as significant binding interactions were only observed with 11 peptide ligands on histone H4. To identify the preferred ligands of the ATAD2B bromodomain, we further characterized their binding affinity using ITC (Table 1, Figures 1C and S2). We discovered that the ATAD2B bromodomain selects both mono- and diacetylated histone ligands, preferentially binding to the histone H4K5ac (1–15) peptide with the strongest affinity ($K_D = 5.2 \pm 1.0 \mu M$), followed by the recognition of several diacetylated ligands including H4K5acK12ac (1-15) and H4K5acK8ac (1-10). The weak interaction of the ATAD2B bromodomain with H4K8ac (1-10) ($K_D = 1164.2 \pm 28.5 \,\mu$ M) (Figure 1C) was confirmed by NMR chemical shift perturbations observed in the bromodomain-binding pocket upon the addition of this ligand (Figure S3A). We also found that the first three residues of the histone H4 tail are crucial for acetyllysine recognition by the ATAD2B bromodomain, especially when the acetylation mark occurs on the K5 or K8 residue (Table 1). Altogether our data indicate that the ATAD2B bromodomain preferentially selects mono- and diacetylated histone modifications

on histones H4 and H2A, and its binding pocket spans at least ten amino acid residues to recognize histone ligands H4K5acK12ac and H4K5acK16ac.

Mapping of the ATAD2B Bromodomain-Binding Pocket.

The X-ray crystal structure of the apo ATAD2B bromodomain has been solved (PDB ID: 3LXJ), but there is no data available on the molecular mechanism of histone recognition. To obtain specific information on how the ATAD2B bromodomain recognizes histone ligands at the molecular level, we first completed the NMR backbone assignment of the ¹⁵N,¹³Clabeled ATAD2B bromodomain (Figure S3B). To outline the Kac-binding pocket within the ATAD2B bromodomain, we used two-dimensional (2D) $^{1}H^{-15}N$ heteronuclear single quantum coherence spectroscopy (HSQC) NMR titration experiments involving the addition of unlabeled, mono- and diacetylated histone ligands to the ¹⁵N-labeled ATAD2B bromodomain protein (Figure 2). Residues Lys 985, Val 987, Glu 991, Glu 997, Val 998, Thr 1007, Tyr 1037, Asn 1038, Asp 1042, Asp 1045, Arg 1051, and Leu 1055 in the ATAD2B bromodomain consistently exhibited the most significant chemical shift perturbations (CSPs) upon the addition of the histone H4K5ac (1-15), H4K5acK8ac (1-10), and H4K5acK12ac (1–15) ligands. These ligands also showed the highest binding affinity as observed by ITC (Table 1). Of these residues, Val 987 lines the hydrophobic Kac-binding pocket, and Tyr 1037 lies adjacent to Asn 1038, which is the universally conserved asparagine known to coordinate the Kac moiety.¹⁹ Residues Glu 991 and Glu 997 reside in the ZA loop. Residues Thr 1007, Arg 1051, and Leu 1055 are present in the aC helix, while residues Asp 1042 and Asp 1045 are located in the flexible BC loop. Consequently, mapping of these residues on the crystal structure of the human ATAD2B bromodomain (PDB ID: 3LXJ) helped visualize the histone ligand interaction site (Figure 2B). Overall, the residues showing large chemical shift perturbations upon the addition of mono- and diacetylated histone ligands are mainly found in two distinct regions of the ATAD2B bromodomain backbone. The first region spans residues 985–1007, which also overlaps with the variable ZA loop and the short aAZ helix. The second region includes residues 1037–1055 that form the BC loop and the N-terminus of the α C-helix region in the ATAD2B bromodomain structure (highlighted in green and magenta, respectively, in Figure 2C). It is interesting to note that certain residues located outside of the canonical Kac-binding pocket also showed large CSPs (above 2σ) (e.g., Thr 1007 and Arg 1051). We suspect this is most likely due to conformational changes occurring within these residues upon histone ligand binding.

Coordination of Mono- versus Diacetylated Histone Ligands.

We also compared the differences in coordination of the mono- versus diacetylated histone ligands (Figure 2A). Overall, a larger number of differences in the chemical shift perturbation pattern were observed between the H4K5ac (1–10) and H4K5acK8ac (1–10) ligands than those between the H4K5ac (1–15) and H4K5acK12ac (1–15) peptides. Notably, longer histone peptides increased the number of CSPs with a standard deviation greater than 2, but only minor differences were seen in the chemical shift perturbation pattern between the H4K5ac (1–15) and H4K5acK12ac (1–15) and H4K5acK12ac (1–15) heptides. Notably, longer histone peptides increased the number of CSPs with a standard deviation greater than 2, but only minor differences were seen in the chemical shift perturbation pattern between the H4K5ac (1–15) and H4K5acK12ac (1–15) ligands. These CSPs occur in residues Arg 979, Phe 980 Val 987, Asp 988 in the ZA loop region, as well as Asp 1045 and Arg 1051 in the *a*C helix. However, since the monoacetylated histone H4K5ac (1–15) peptide showed a ~3-fold increase in binding affinity than the H4K5acK12ac (1–15) peptide (as measured by

ITC), the limited difference in the CSP pattern could indicate that the second Kac group is not coordinated directly by the ATAD2B bromodomain but rather lies outside the binding pocket. On the other hand, there are several significant differences in the CSP pattern between the shorter histone H4K5ac (1–10) and H4K5acK8ac (1–10) ligands. CSP differences greater than 1σ were observed for residues Thr 1010, Lys 1021, Asn 1038, and Asp 1045. Residues Leu 974, Arg 979, Thr 1007, Tyr 1037, and Ala 1065 all demonstrated a CSP difference between 0.5 and 1.0σ . Thus, these residues displaying larger chemical shift patterns upon the addition of the diacetylated histone H4K5acK8ac (1–10) ligand are either due to conformational changes occurring in the ATAD2B bromodomain-binding pocket upon complex formation or due to the direct interaction of these residues with the second Kac group.

Bromodomain-Binding Pocket Residues Important for Histone Ligand Recognition.

Next, we sought to investigate the residues critical for the bromodomain-ligand interaction. In cloning the full-length ATAD2B cDNA for functional studies, we discovered a splice variant in the ATAD2B mRNA that is created by an alternative 5' splice donor site between exons 21 and 22 of ATAD2B that encode the bromodomain (Figure 3A,B). This novel splicing event results in the exclusion of residues 988-992 (VDIEE) in the ZA loop (Figure 3C) of the canonical ATAD2B bromodomain, generating a shorter variant (ATAD2B_{short}). Interestingly, despite having an overall comparable gene structure to ATAD2B, we failed to detect any splicing events in the ATAD2 bromodomain exons (Figure S4A,B). We used ITC assays to compare the ligand binding properties of the ATAD2B_{short} to the canonical ATAD2B bromodomain. In addition, we tested several conserved amino acids in this region via site-directed mutagenesis, including Tyr 995, Tyr 1037, and Asn 1038 residues. The locations of each of these amino acids are mapped onto the ATAD2B bromodomain-binding pocket in Figure 3C. For these binding assays, we used the five major ATAD2B bromodomain histone ligands identified from our ITC assays (Table 2 and Figure S5). Mutation of residues Tyr 995 and Tyr 1037 to alanine abolished binding to the mono- or diacetylated histone ligands. In contrast, the ATAD2B Asn1038 to alanine mutation did not fully prevent histone ligand binding, instead a reduced binding activity for the major ATAD2B histone ligands was still observed (Table 2 and Figure S5). Interestingly, the ATAD2B_{short} was unable to bind to any of the histone peptide ligands tested (Table 2 and Figure S5). To verify that the loss of histone ligand binding was not due to protein misfolding after the mutation, we used circular dichroism (CD) to analyze the secondary structures of each of the mutant ATAD2B bromodomains tested (Table 3 and Figure 3D). Analysis of the ATAD2B mutants and the ATAD2B_{short} variant revealed no major alterations in the bromodomain secondary structure. However, we further characterized the melting temperature (T_m) of the ATAD2B bromodomain by a thermal shift assay and found that the $ATAD2B_{short}$ variant has a significantly lower T_m when compared to the full-length bromodomain (Figure 3E), presumably due to the destabilization of the bromodomain fold. Overall, our data highlights the critical importance of the ZA loop in ligand recognition and suggests that alternative splicing could be a cellular mechanism regulating ATAD2B bromodomain ligand recognition.

Recognition of the ATAD2 Bromodomain Inhibitor Compound 38 (GSK C-38).

ATAD2 overexpression is strongly correlated with cancer progression,^{20–22} driving the search for potent ATAD2 bromodomain inhibitors. Compound 38 (C-38) was developed by GlaxoSmithKline as the lead molecule possessing significant binding selectivity for the ATAD2 bromodomain over the BRD4-BD1 bromodomain (bromodomain and extraterminal (BET) bromodomain subfamily II), with a binding affinity of 90 nM.¹⁷ We tested the binding of C-38 against the ATAD2/B bromodomains by ITC and confirmed that this inhibitor interacts with the ATAD2 bromodomain with a K_D of 93.3 ± 2.8 nM, while the ATAD2B bromodomain binds with a K_D value of 166.9 ± 5.6 nM (Table 1 and Figure S2S,T). Furthermore, the ATAD2B_{short} VDIEE variant failed to interact with C-38 (Table 2).

To gain insights into why the binding affinity of the ATAD2B bromodomain for C-38 is almost twofold lower than the ATAD2 bromodomain,¹⁷ we used molecular replacement with the apo ATAD2B bromodomain (PDB ID: 3LXJ) to solve the X-ray crystal structure of this compound in complex with the ATAD2B bromodomain. This structure provides the molecular details of the inhibitor interaction (Table 4 and Figure 4) and demonstrates that coordination of C-38 occurs through a combination of hydrogen bonds and hydrophobic interactions (Figure 4A). The guanidinium group of Arg 1051 makes specific hydrogenbond contacts to the sulfone oxygen atoms of ring E in C-38, while the OD1 and OD2 carboxyl groups of Asp 1042 and Asp 1045 contact the piperidine nitrogen in ring D. The universally conserved Asn 1038 makes several hydrogen bonds to C-38. Asn 1038 binds the exocyclic amino group between the D and B rings and forms H-bonds with both the nitrogen and oxygen atoms in the lactam ring C. The hydroxyl group of Tyr 995 also coordinates with the oxygen atom of the lactam ring C through an ordered water molecule. Important hydrophobic interactions occur between C-38 and the side chains of the gatekeeper residues Ile 1048 and Ile 982 in the NIF shelf of the ATAD2B bromodomain (RVF shelf in ATAD2). Val 992, Val 987, and Tyr 1037 also contribute to the hydrophobic coordination of C-38 by forming part of the ATAD2B bromodomain-binding pocket wall. The conserved Asn 1038 seems to play a large role, especially deeper in the binding pocket, and is likely the driving force maneuvering the inhibitor into the bromodomain-binding pocket in a favorable alignment. Of note, many of the bromodomain residues involved in the coordination of the C-38 inhibitor also make conserved contacts with the acetylated histone ligands (Figure 2 and Table 2). Overall, our structural model indicates that the coordination of C-38 by the ATAD2B bromodomain is highly conserved with the ATAD2 bromodomain. However, some key differences that may contribute to the change in binding affinity are highlighted below.

DISCUSSION

The ATAD2 bromodomain, which is 74.7% identical and 94.4% similar to the ATAD2B bromodomain, has been studied extensively due to its adverse association with overall survival rates for several solid tumors.^{21,23–26} Previous studies have identified several histone ligand interactions of the ATAD2 bromodomain; however, little is known about the paralogous bromodomain found in ATAD2B.^{7,15,16} Our dCypher peptide array data show that the ATAD2/B bromodomains predominantly select acetyllysine modifications on histone H4; however, the ATAD2B bromodomain demonstrates a broader substrate

specificity, not only binding to a larger number of histone H4 ligands but also interacting with acetyllysine on histones H2A and H2A.X. The ATAD2B bromodomain is also able to recognize larger acyl modifications including propionyllysine and butyryllysine, but not crotonyllysine, similar to the BRD9 family IV bromodomain.¹⁰

Prior to this study, Leachman et al.¹² published one of the only sources of information on the ATAD2B protein. They studied the expression of ATAD2B in chicken embryos and human tumors with a polyclonal antibody raised against human ATAD2B. In 2012, the X-ray crystal structure of the ATAD2B (KIAA1240) bromodomain was deposited as an apo structure (PDB ID: 3LXJ) as part of a large-scale structural analysis of human bromodomains.⁷ In the SPOT peptide array, ATAD2B demonstrated very strong interactions with acetylated histone peptides H2AK36ac, H2BK43ac, H2BK85ac, H3K56ac, H4K5ac, and H4K59ac.⁷ It is clear from our experience of determining the histone ligands of the BRPF1 bromodomain that high-throughput methods are important for identifying potential ligands, but more traditional biochemical and biophysical approaches are necessary to validate the interactions and measure the binding affinities.²⁷ It is not certain whether acetylated lysines found outside of the N-terminal histone tail region (usually defined as the first 30 amino acids) would be sterically available for bromodomain recognition since they are located in the globular core domain of the histone proteins. Unfortunately, more specific follow-up assays were not performed on the ATAD2B bromodomain to confirm these interactions.

Previous studies indicated that the ATAD2 bromodomain has a stronger binding preference for histone H4K12ac over H4K5ac, with reported affinities of 2.5^{14} and $22 \mu M$,¹⁶ respectively. In contrast, our ITC binding data demonstrated that the ATAD2B bromodomain preferentially selects the histone H4K5ac ligand over H4K12ac. Additionally, a timeresolved fluorescence energy transfer (TR-FRET) assay showed that the ATAD2 bromodomain recognizes multiple acetyllysine combinations on histone H4 including H4K5acK12ac (1-25) and H4K5acK8acK12acK16ac (1-25).¹⁶ We also found that the ATAD2B bromodomain recognizes several diacetylated histone ligands including H4K5acK8ac, H4K5acK12ac, H4K5acK16ac, H4K8acK16ac, and H4K12acK16ac, albeit with weaker affinities. Both bromodomains appear to have the overlapping ligand-binding ability and recognize H4K5acK12ac.¹⁶ Recognition of this diacetylated histone H4K5acK12ac ligand was shown to be important for the biological function of the ATAD2 bromodomain, as this modification appears on newly synthesized histones following DNA replication.^{16,28} The histone H4K5acK8ac modification has been linked to highly active gene promoters.²⁹ A previous study proposed that acetylation of histone H4 occurs progressively, starting at H4K16ac, then moving toward the N-terminus via K12, K8, and finally K5.^{30,31} This model suggests that the H4K5acK8ac mark represents a hyperacetylated state of histone H4.32 Since our ITC data demonstrated a high binding affinity of the ATAD2B bromodomain with the H4K5acK8ac ligand, our results are the first to show a possible association of ATAD2B with hyperacetylated histone H4. Dysregulation of histone acetylation patterns has been linked to cancer development,³³ and certain Kac modifications have been shown to increase and/or decrease in different cancer subtypes.³⁴ Overall, our data indicate that the ATAD2/B bromodomains possess slightly different histone-binding specificities despite being highly conserved paralogues.

The flexibility of the bromodomain reader module appears to be a key factor in the selection and recruitment of histone ligands. Using a molecular dynamics (MD) approach, Langini et al.35 simulated the ATAD2 bromodomain-binding trajectories of the H4K5acK12ac (1-16) ligand with either a buried K5ac and K12ac or just the bromodomain in the apo state.³⁵ They highlighted the role of Glu 1017, Tyr 1021, and Ile 1074 in ATAD2 (corresponding to Glu 991, Tyr 995, and Lys 1048 in ATAD2B), in the ZA loop that engages in "open" or "closed" conformational states of the loop. They also suggested that several negatively charged residues on the ZA loop could play a key role in driving binding of the histone tail, which is composed of positively charged residues such as arginine and lysine. Our NMR results indicate significant chemical shift perturbations for residues Glu 991 (>1 σ), Tyr 995 (>1 σ), and residue Glu 997 (~ 2σ) occur during titrations with mono- or diacetylated H4 histone tail ligands, thus confirming the involvement of the bromodomain ZA loop in coordinating the histone ligands. The MD simulations of the ATAD2 bromodomain also detected molecular contacts between the histone ligand and a patch of negatively charged residues on the ZA loop.³⁵ These residues included Glu 1017 and Asp 1020, which correspond to residues Glu 991 and Asp 994 in the ATAD2B bromodomain. Previously, large conformational changes were observed in these regions of the ATAD2 bromodomain structure as reported by Poncet-Montange et al.;¹⁴ however, our NMR data show that larger chemical shift perturbations occur in the BC loop than in the ZA loop region in the ATAD2B bromodomain. Moreover, many of the conserved residues involved in ligand coordination for the ATAD2 bromodomain, such as the Phe in the RVF shelf residues (ATAD2 1007-1009, ATAD2B 981–983) and the gatekeeper residue (Ile 1074/Ile 1048), did not demonstrate significant $(>0.5\sigma)$ chemical shift perturbations upon ligand binding to ATAD2B. From these data, we hypothesize that Kac ligand recognition is initiated by structural changes in the flexible loop regions of the ATAD2B bromodomain that recruits the histone ligand to the bromodomainbinding pocket, resulting in specific hydrogen-bonding and hydrophobic interactions following ligand docking. To gain insights into how other bromodomains coordinate the H4K5acK8ac ligand, we analyzed the structures of the BRD4-BD1 and BRDT-BD1 in complex with H4K5acK8ac peptides^{36,37} and compared them to the ATAD2/B bromodomain-binding sites. We observed similarities in the type of residues involved in K5ac recognition in the primary binding site. However, the residues lining the K8ac recognition site in BRD4 and BRDT BRD1 are not conserved in ATAD2/B and may explain the differences in the histone tail binding preferences and binding mode observed between the ATAD2/B and the BRDT-BD1 bromodomains.

Interestingly, our previous NMR studies on the BRPF1 bromodomain (family IV BRD) showed similar chemical shifts in both the ZA and BC loop regions.²⁷ Thus, inherent mobility in the ZA and BC loop regions appears to be a common feature of the bromodomain-binding pockets, and they may retain unordered properties even when the ligand is bound. In Figure 2, Glu 991 shows significant chemical shift changes upon the addition of nearly all histone ligands tested. Glu 991 corresponds to residue Asp 36 in the BRPF1 bromodomain, which also demonstrated one of the largest chemical shift perturbations upon ligand binding.²⁷ However, the mutation of Asp 36 to Ala in the BRPF1 bromodomain did not significantly affect its histone-binding activity. Therefore, we suspect that Glu 991 in ATAD2B may play an important role in the initial recruitment of the

acetylated ligands into the bromodomain-binding pocket. Overall, our data support the suggestion by Langini et al.³⁵ that dynamic motions in the binding pocket loops are likely important for the initial selection of the histone ligand, while ligand specificity is conferred by conserved amino acids that do not demonstrate large conformational changes upon ligand binding.³⁵ Thus, flexibility in the ZA and BC loop regions allows for rapid on/off rates of the histone ligand and cooperative coordination of adjacent acetyllysine marks, but the universally conserved asparagine, the gatekeeper residue, and the NIF/RVF shelf motif in the ATAD2/B bromodomains drive histone ligand recognition at the molecular level.

Another important and interesting distinction between the ATAD2/B bromodomains is the discovery of a functionally distinct splice variant in the ATAD2B mRNA that is not found in the ATAD2 mRNA. Our data indicate that an alternative 5' splice donor site of the ATAD2B bromodomain exons produces a bromodomain that lacks five amino acids in the ZA loop of the Kac-binding pocket. Importantly, this variant does not interact with histone ligands nor with the small-molecule inhibitor C-38. We performed directed RT-PCR splicing analysis and RNA-seq analysis of publicly available data³⁸ to assess the expression patterns of ATAD2B bromodomain isoforms across a wide variety of cell types (Figure S6). Overall, we consistently detected the comparable expression of the ATAD2B canonical and ATAD2B_{short} isoforms across different samples. There appears to be no direct correlation of ATAD2B_{short} isoform variant expression with breast cancer or across normal tissues.

Even though we failed to identify any evidence of alternative splicing in the ATAD2 bromodomain-encoding exons (Figure S4), such isoforms have been observed in other bromodomain-containing proteins. For example, BRPF1 bromodomain splice isoform A inserts six residues into the ZA loop, which effectively impairs the binding of tetra-acetylated histone H4 peptides and small-molecule inhibitors.³⁹ Another splice variant observed in the NURF chromatin remodeling complex removes the C-terminal PHD finger and bromodomain and results in a spermatocyte arrest phenotype.⁴⁰ Additionally, a splice variant of p300 was described in a T-lymphoblastic cell line that generates a bromodomain lacking seven amino acid residues.⁴¹ Thus, we hypothesize that alternative splicing may be a potential regulatory mechanism controlling ATAD2B activity in vivo.

Our ITC binding data on the interaction of the ATAD2B bromodomain with the GlaxoSmithKline ATAD2 bromodomain inhibitor C-38 (Table 1 and Figure S2S) is in line with the previously published observation that C-38 binds well to both the ATAD2/B bromodomains in the nanomolar range.¹⁷ In addition, we solved the structure of the ATAD2B bromodomain with C-38 and identified molecular contacts that are important for inhibitor coordination. The X-ray crystal structure of the ATAD2B bromodomain in complex with C-38 (PDB ID: 6VEO) is highly conserved with the structure of the ATAD2 bromodomain in complex with compound 42 (C-42, PDB ID: 5A83). C-42 was also developed by GlaxoSmithKline as a derivative of C-38 with increased cell membrane permeability.¹⁷ C-38 differs from C-42 only by the presence of one nitrogen atom in the lactam ring B, which is a carbon in the latter. The coordination of C-42 in the ATAD2 bromodomain is nearly identical to the coordination of C-38 by the ATAD2B bromodomain (compare Figures 4A,B, and S7). The hydrogen-bonding pattern is highly conserved, with important H-bonds formed in the universally conserved asparagine, Asn 1038 and Asn 1064

in the ATAD2/B bromodomains, respectively. In the ATAD2-C-42 structure, there are also H-bonds in the backbone nitrogen of Asp 1014 and the side chains of Asp 1071 and Arg 1077.

Notably, there are slight differences in the H-bond coordination of C-38 and C-42 between the ATAD2B and ATAD2 bromodomains (Figure 4A,B). For instance, the backbone nitrogen of Asp 1014 in ATAD2 makes an H-bond contact with the nitrogen atom of pyridine ring A in C-42. In ATAD2B, the C-38 ligand is positioned closer to Asp 1042 and 1045, weakening the interaction between Asp 988 and the pyridine ring nitrogen, and loss of this contact is likely related to the lower affinity for C-38 by the ATAD2B bromodomain. The RVF shelf motif in the ATAD2 bromodomain is also the main region of the Kac-binding pocket that differs between the ATAD2/B bromodomains, which is a NIF shelf motif in ATAD2B. Notably, the substitution of the shelf motif Val in ATAD2 to Ile at position 982 in the ATAD2B bromodomain slightly changes the shape complementarity of the binding pocket and likely contributes to the difference observed in the binding affinity between these two bromodomains.

Overall, the ATAD2/B bromodomain Kac-binding pockets are very highly conserved, and finding inhibitors that will differentiate between these two bromodomains will be challenging. Even so, a notable success was the discovery of BAY-850, an isoform-specific small molecule shown to selectively target only the ATAD2 bromodomain.⁴² BAY-850 appears to have a unique mode of action and causes dimerization of the ATAD2 bromodomain to inhibit its interaction with chromatin. Thus, the optimization of new inhibitors to take better advantage of the small differences between the ATAD2/B bromodomains could successfully improve their binding specificity of bromodomain inhibitor compounds. Indeed, one region with significant differences between the ATAD2/B bromodomains is at the RVF shelf motif found in ATAD2 (residues Arg 1007, Val 1008, and Phe 1009), which forms a NIF shelf in the ATAD2B bromodomain (residues Asn 981, Ile 982, and Phe 983) (Figure 4A).

CONCLUSIONS

Collectively, the results from this study describe the histone ligands of the ATAD2B bromodomain and outline many important features of the binding pocket that contribute to ligand selection and specificity. This information will be valuable for the development of selective ATAD2B bromodomain inhibitors or tool compounds that can be used to further investigate the biological function of the poorly characterized ATAD2B protein. We discovered that the ATAD2B bromodomain is a diacetyllysine reader module; however, the significance of histone H4K5acK8ac ligand binding is yet to be determined. Linking the recognition of histone H4K5acK8ac to particular cellular outcomes will be essential for understanding the unique role of the ATAD2B bromodomain, and how it functions independently from ATAD2. Our NMR chemical shift perturbation experiments identified several amino acids that differed between the coordination of mono- and diacetylated histone ligands. It is interesting to note that most of the differences between the chemical shift perturbation pattern in the coordination of H4K5ac (1–15) and H4K5acK12ac (1–15) occur in residues that are also involved in hydrogen-bond contacts with the C-38 inhibitor.

Additionally, differences in the chemical shift perturbation pattern of key residues provide new insights into why this bromodomain preferentially selects histone ligands with multiple Kac modifications.

Thus, it will be essential to solve the structure of the ATAD2B bromodomain with diacetylated histones to discover the molecular details of the binding mechanism. However, our results demonstrate that although the ATAD2/B bromodomain modules are highly conserved paralogues, they preferentially recognize different subsets of acetylated histone ligands and appear to be regulated via different cellular mechanisms. This suggests that these two bromodomain-containing proteins are involved in divergent biological pathways and may contribute to cancer development in different ways. It is also important to note that while the ITC and NMR experiments were robust, our biochemical and biophysical analysis may not be directly translated to the cell, where the in vivo abundance of the H4K5acK8ac and H4K5acK12ac modifications may be relatively small compared to either the H4K5ac or H4K12ac ligands, which also bind strongly to the ATAD2B bromodomain. Thus, further in vivo experimentation will be necessary to fully appreciate the biological significance of these interactions. In conclusion, we describe here the novel histone-binding specificity of the ATAD2B bromodomain. Our study outlines the important residues involved in monoand diacetylated histone ligand recognition, as well as in coordination of the small-molecule bromodomain inhibitor C-38. Our study also revealed that alternative splicing may be a unique molecular mechanism regulating the binding activity of the ATAD2B bromodomain. These data provide insight into how they may be specifically inhibited to further advance our understanding of differences in the roles of the ATAD2/B bromodomains.

METHODS

Plasmid Construction.

Human ATAD2/B cDNA (UniProt codes Q9ULIO and Q6PL18) was a gift from Nicole Burgess-Brown (Addgene plasmid # 38916 and 39046).⁷ The ATAD2 bromodomain region (residues 981–1108) and the ATAD2B bromodomain region (residues 953–1085) were PCRamplified and cloned into the pDEST15 vector encoding an N-terminal GST tag using the Gateway Cloning Technology (Invitrogen).²⁷ ATAD2B bromodomain mutants N1038A, Tyr995Ala, Tyr1037Ala, and the DIEEV deletion (residues 988–992) were generated using QuikChange site-directed mutagenesis (Agilent Technologies).⁴³ The DNA sequence of each was verified (University of Vermont Cancer Center Advanced Genome Technologies Core) and then transformed into *Escherichia coli* Rosetta 2(DE3)pLysS competent cells (Novagen).

Protein Expression and Purification.

E. coli cells containing the GST-tagged ATAD2B wild-type or mutant bromodomain were grown in 4 L of Terrific broth (TB) or ¹⁵NH₄Cl-supplemented or ¹⁵NH₄Cl/¹³C₆ D-glucosesupplemented minimal media at 37 °C. The culture temperature was dropped to 20 °C for 1 h when the OD₆₀₀ reached 1. Protein expression was then induced by the addition of 0.25 mM isopropyl β -D-1-thiogalactopyranoside (IPTG), and the cells were harvested by pelleting after 16 h of incubation at 20 °C with shaking at 225 rev min⁻¹. The bacterial pellet

was resuspended in 100 mL of lysis buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.05% Nonidet P-40, 1 mM dithiothreitol (DTT)) containing 1 mL of lysozyme, and the cells were lysed by sonication. The cell lysate was cleared by centrifugation (10 000 rev min⁻¹ for 20) min). The supernatant was added to 15 mL of glutathione agarose resin, which binds up to 40 mg of purified recombinant GST protein per milliliter of resin (Thermo Scientific), and incubated on ice (4 °C) while agitating for 120 min. After incubation, the suspension was centrifuged for 5 min at 500g to collect the beads. The collected beads were poured into a 25 mL Econo-Column Chromatography Column (Bio-Rad) and washed with four column volumes of wash buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 1 mM DTT). The GST tag was cleaved overnight at 4 °C by the addition of PreScission Protease (~100 µL at 76 mg mL⁻¹) (GE Healthcare), and the eluted ATAD2B bromodomain protein was concentrated to a total volume of approximately 3 mL. For isothermal titration calorimetry (ITC) or circular dichroism (CD) experiments, the protein was concentrated and dialyzed into buffers consisting of 20 mM NaH₂PO₄, pH 7.0, 150 mM NaCl or 50 mM NaH₂PO₄, pH 7.0, and 50 mM NaCl, respectively. For NMR experiments, the uniformly ¹⁵N-labeled and the ¹⁵N,¹³C double-labeled ATAD2B bromodomain was buffer-exchanged with 20 mM Tris-HCl, pH 6.8, 150 mM NaCl, 10 mM DTT, and 10% D₂O. For X-ray crystallography, the protein was further purified using fast-protein liquid chromatography on an AKTA purifier UPC 10 (GE Healthcare) over a HiPrep 16/60 Sephacryl S-100 high-resolution gel filtration column (GE Healthcare) equilibrated with crystallography buffer (25 mM N-(2-hydroxyethyl)piperazine-N'-ethanesulfonic acid (HEPES), pH 7.5, 150 mM NaCl, and 1 mM DTT). Eluted fractions corresponding to the ATAD2B bromodomain were pooled and concentrated to 30 mg mL⁻¹ at 4 °C. The protein concentration was determined either by the Pierce BCA protein assay kit (Thermo Scientific) and measuring the absorption at 595 nm or by measuring the protein absorbance at 280 nM. The absorption values were then converted to micromoles/millimoles using a ATAD2B bromodomain extinction coefficient of 4470 M⁻¹ cm⁻¹. The purity of the ATAD2B bromodomain was verified by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gels stained with GelCode Blue Safe protein stain (Thermo Scientific).

Histone Peptide and Bromodomain Inhibitor Synthesis.

Biotinylated histone peptides for the dCypher assays were from EpiCypher (Resources Table A). Histone peptides for other studies were either synthesized by the Peptide Core Facility at the University of Colorado Denver, GenScript, or by BioMatic BioMatic with a free N-terminus and an amidated C-terminus. The peptides, supplied as the trifluoroacetic acid (TFA) salt, were purified by high-performance liquid chromatography (HPLC) and were confirmed to have a purity 96%. Their chemical identities confirmed by mass spectroscopy (see Supporting Information for the HPLC/MS data). Peptide sequence information is listed in Table 1. Compound 38 (C-38) or 8-(((3*R*,4*R*)-3-((1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-methoxy)-piperidin-4-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7- naphthyridin-2(1*H*)-one is a potent ATAD2 bromodomain inhibitor developed by GlaxoSmithKline in 2015.¹⁷ C-38 was synthesized by Dr. Jay Bradner's laboratory according to the previously published procedure and isolated as the TFA salt.¹⁷ The molecule was characterized by one-dimensional (1D) ¹H NMR (500 mHz, methanol-*d*₄) 1.80 (m, 2H), 1.89 (m, 1H), 2.09 (m, 3H), 2.23 (s, 3H), 2.44 (m, 1H), 2.53 (s, 3H), 2.99 (m,

2H), 3.06 (m, 2H), 3.25 (m, 2H), 3.48 (m, 1H), 3.57 (m, 2H), 3.68 (m, 1H), 3.94 (m, 1H), 4.53 (m, 1H), 7.69 (s, 1H), 7.84 (s, 1H), 8.04 (s, 1H), 8.54 (s, 1H), 8.57 (s, 1H) and is consistent with the previously described compound.¹⁷ LCMS: 512.41 (M + H).

dCypher Binding Assays.

Two phases of dCypher testing on the AlphaScreen platform were performed as previously described.44,45 In phase A, the GST-tagged ATAD2/B bromodomains were titrated to positive and negative control biotinylated peptides to determine binding curves (including the level of sensitivity, signal saturation, and signal over background; Figure S1A,B). In phase B, a single optimal GST-bromodomain concentration was used to probe the complete biotinylated peptide panel (Resources Table A). For each phase, 5 µL of GST-tagged ATAD2/B bromodomain (4 nM and 500 pM, respectively) was incubated with 5 μ L of biotinylated peptides at 100 nM for 30 min at room temperature in the epigenetics assay buffer (PerkinElmer AL008; diluted to 1× and supplemented with 1 mM tris(2carboxyethyl)phosphine) (TCEP) in a 384-well plate. A mixture of 10 μ L of 2.5 μ g mL⁻¹ glutathione acceptor beads (PerkinElmer) and 5 μ g mL⁻¹ streptavidin donor beads (PerkinElmer) was prepared in a peptide assay buffer and added to each well. The plate was incubated for 60 min at room temperature in subdued lighting, and the AlphaLISA signal was measured on a PerkinElmer 2104 EnVision (680 nm laser excitation, 570 nm emission filter ±50 nm bandwidth). Each binding interaction was performed in duplicate. The dCypher assay signal was plotted separately for the ATAD2 bromodomain and the ATAD2B bromodomain array data, where the data was scaled by the strongest average fluorescent intensity signals for each bromodomain.

Isothermal Titration Calorimetry.

ITC experiments were carried out at 5 °C with a MicroCal iTC200 instrument (Malvern Paralytical). Each of the ATAD2B bromodomain proteins and histone peptide samples were dialyzed in ITC buffer containing 20 mM NaH₂PO₄, pH 7.0, and 150 mM NaCl. Calorimetric titration was performed by titrating each histone tail ligand (5 mM) with 0.2 mM ATAD2B bromodomain protein in the sample cell in a series of 19 individual injections of 2 μ L, at time intervals of 150 s with a stirring speed of 750 rpm. These were preceded by a preliminary injection of 0.5 µL of 5 mM peptide sample, which was excluded from the data integration and calculation of K_D 's. To determine the heat of dilution of the titrant peptides in the experimental buffer, control experiments were conducted under identical conditions. As part of data analysis, this was deducted from the experimental data. The obtained change-in-heat peaks were then analyzed by the Origin 7.0 program (OriginLab Corporation) and used to calculate binding affinities. Experiments in which binding occurred were performed in triplicate, while runs with no binding were performed in duplicate. The average of the three runs was taken as the mean $K_{\rm D}$, and the standard deviation was calculated from the mean. The $K_{\rm D}$ values and standard deviations for the binding affinity of each ligand tested are reported in Table 1.

NMR Spectroscopy.

All chemical shift perturbation experiments were conducted using uniformly ¹⁵N-labeled ATAD2B bromodomain prepared at 0.5 mM in buffer containing 20 mM Tris–HCl, pH 6.8,

150 mM NaCl, 10 mM DTT, and 10% D₂O. Titration mixtures (35 μ L) of the protein and peptide were made at concentration ratios of 1:0, 1:0.25, 1:0.5, 1:1.1, 1:2.5, and 1:5 for the unlabeled histone tail peptides containing specific acetyllysine modifications. Two-dimensional (2D) ¹⁵N heteronuclear single quantum coherence (HSQC) experiments for all samples were run at 25 °C on a 600 MHz Bruker AVANCE III spectrometer equipped with a *z*-gradient 1.7 mm TCI probe at the National Magnetic Resonance Facility at Madison (NMRFAM). The NMR data were collected with ¹H and ¹⁵N radio frequency pulses applied at 4.745 parts per million (ppm) and 116 ppm, respectively. A total of 1024 × 128 complex data points with spectral widths of 16 and 30 ppm, respectively, were collected along the ¹H and ¹⁵N dimensions, with 32 scans per flame ionization detector (FID) and an interscan delay of 1.0 s, resulting in a total experimental time of about 160 min for each HSQC spectrum. Transformed spectra at each titration point were overlaid and analyzed to characterize the relevant residues affected by the interaction between the ATAD2B bromodomain and the histone peptides. Normalized chemical shift changes were calculated as described in ref 46 using the equation

$$\Delta \delta = \sqrt{\Delta \delta_{\rm H}^2 + \left(\alpha \cdot \Delta \delta_{\rm N} \right)^2}$$

where a = 0.14 for all residues except for glycine, which has a = 0.2, and $\delta_{\rm H}$ and $\delta_{\rm N}$, respectively, are the changes in proton and nitrogen chemical shifts in ppm. To map the chemical shift perturbations onto the ATAD2B bromodomain surface, we calculated the standard deviation (σ) of the Euclidean chemical shift change overall residues of all bromodomain/peptide combinations. Residues whose chemical shift change was greater than 0.5σ were colored yellow, while residues with chemical shift changes greater than 1σ and 2σ were colored orange and red, respectively.

To obtain the backbone resonance assignments, the ¹⁵N, ¹³C double-labeled ATAD2B bromodomain was prepared at about 1 mM in buffer containing 20 mM Tris-HCl, pH 6.8, 150 mM NaCl, 10 mM DTT, and 10% D₂O. Assignment-directed data collection algorithm utilizing a probabilistic toolkit in NMR (ADAPT-NMR) was used to optimize simultaneous fast data collection and automated NMR assignment of the HNCO, HN(CA)CB, HNCA, HN(CO)CA, HN(CA)CO, CBCA(CO)NH, and C(CCO)NH spectra by achieving reduced dimensionality (2D).⁴⁷ These experiments were run at 25 °C on a 600 MHz Agilent VNMRS spectrometer equipped with a 5 mm Z-axis pulsed-field gradient triple resonance cold probe. The NMR data for all experiments were collected with the universal carrier position of ¹H, ¹⁵N, ¹³C^a (shaped pulse), ¹³C^{aliphatic} (¹³C^{a/b} or ¹³C^b, shaped pulse), and ¹³C' (shaped pulse) applied at 4.76 ppm (H₂O frequency), 118, 56, 45, and 176 ppm, respectively. A total of 1024, 32, 64, 64, and 64 complex data points with spectral widths of 16, 36, 32, 70, and 22 ppm, respectively, were collected along the ¹H, ¹⁵N, ¹³C^a, ¹³C^{aliphatic}, and ¹³C' dimensions. Processing and analysis for all data were conducted automatically with ADAPT-NMR.^{47,48} After one day of the ADAPT-NMR run, an 84.7% assignment level was achieved. To generate visualized assignment labels on the 2D ¹H-¹⁵N HSQC spectra, PINE-SPARKY and NMRFAM-SPARKY were used. 49-51

Circular Dichroism Spectroscopy.

Circular dichroism (CD) spectra were recorded on a JASCO J-815 CD spectrometer (JASCO, Japan) at 25 °C in a 1.6 cm cell. ATAD2B bromodomain wild-type (WT) or mutant proteins were dialyzed in 50 mM NaPO₄, pH 7.0, and 50 mM NaCl buffer and diluted to concentrations between 0.1 and 0.5 μ M. CD spectra were measured from 199 to 260 nm. Two spectra were measured and averaged for each mutant bromodomain protein sample and the wild-type protein. Spectra were analyzed using K2D3 structure prediction software to determine the percent α -helical and β -sheet contents.⁵²

X-ray Crystallography.

The purified ATAD2B bromodomain protein (1.9 mM) was mixed with C-38 (4 mM) in a 1.5 mL microcentrifuge tube. Crystallization screens were set up using the sitting-drop method in 96-well VDX plates (Hampton Research), with drops consisting of 1 µL of protein/peptide mixture plus 1 μ L of reservoir solution and a reservoir volume of 100 μ L. The ATAD2B bromodomain was cocrystallized with the C-38 inhibitor in Index Screen condition no. 66 [0.2 M ammonium sulfate, 0.1 M bis-Tris, pH 5.5, 25% (w/v) poly(ethylene glycol) 3350] at 4 °C. The C-38 crystals from Index Screen condition no. 66 were reproduced in hanging drops (1 μ L of protein solution plus 1 μ L of mother liquor) using 24well VDX plates (Hampton Research) containing 500 µL of mother liquor in the reservoir. The crystals were mounted directly from the drop using the CrystalCap SPINE HT system with 100 μ M nylon loops (Hampton Research) with the notches broken at 18 mm. The crystals were cryoprotected by incubating the crystal in the cryoloop over 500 μ L of 40% methanol in water solution inside the cryovial, where the liquid nitrogen escape holes were blocked with clay. After a 2 min incubation period, the crystal was flash-frozen directly in the liquid nitrogen stream at 100 K on the beamline much as described in Farley et al.⁵³ Data for the C-38 crystal was collected at the Center for X-ray Crystallography at the University of Vermont on a Bruker D8 Kappa Quest generator (Bruker-AXS Inc., Madison, WI, USA) equipped with a Photon 100 CMOS detector and a Cryostream 700 from Oxford Cryosystems. The diffraction data were processed using the Proteum3 suite (Bruker-AXS Inc., Madison, WI). The structure was solved by molecular replacement using Phaser with the apo ATAD2B bromodomain structure (PDB ID: 3LXJ) as the starting model.⁵⁴ The model was built using COOT to add the C-38 inhibitor, and PHENIX and COOT were used for iterative rounds of refinement, density modification, and model building.^{55,56} The final structure at 2.4 Å resolution was validated using MolProbity and Polygon.^{57,58}

Thermal Shift Assay.

The thermofluor assay or the thermal shift assay is often used for the rapid determination of protein thermal stability in different in vitro conditions by monitoring the unfolding of the protein at increasing temperatures. The melting point (T_m) of the wild-type or mutant ATAD2B bromodomain was calculated from an increase in the SYPRO orange dye fluorescence intensity. It was performed using a 96-well clear plastic plate using an Eppendorf Mastercycler Realplex2 qPCR machine. Triplicates of 100 μ L of 5 μ M ATAD2B WT and the ATAD2B DIEEV mutant were premixed with 5 μ M SYPRO orange dye in 20 mM sodium phosphate, 150 mM NaCl, and pH 7.0 for T_m calculations. Wells containing

only buffer with 5 μ M dye were used for baseline correction. The plate was sealed with an optically clear adhesive tape to prevent sample loss during heating. The temperature was gradually ramped up from 25 to 95 °C while monitoring the change in fluorescence intensity of the dye. GraphPad Prism software was used to analyze the data and calculate the melting point of the protein sample by applying nonlinear regression using the melting Boltzmann equation:

$$Y = \text{bottom} + (\text{top-bottom}) / \left(1 + \exp\left(\frac{T_{\text{m}} - X}{\text{slope}}\right)\right)$$

RT-PCR Analysis.

Splicing analysis: Direct-zol RNA MiniPrep kit (Zymo Research) was used to isolate RNA in Trizol reagent (Thermo Scientific), and cDNA was synthesized using 1 μ g of total RNA with Invitrogen SuperScript II Reverse Transcriptase and oligo dT primers (Thermo Scientific) according to the manufacturer's instructions. PCR products were resolved on a 24% TBE gel and visualized using ethidium bromide or cloned into pGEM-T (Promega) and Sanger sequenced. Primer sequences: ATAD2B_EXON_F: TGACCTCATCTGTAGCAATGCT and ATAD2B_EXON_R: TCAGCTGCAATGATAGCATGTGCA.

RNA-seq Analysis.

RNA-seq alignment files were obtained from the Cancer Cell-Line Encylopedia.⁵⁹ Reads spanning the splice junctions between exon 21 and exon 22 of ATAD2 and ATAD2B were quantified using seqsetvis.⁶⁰ Splicing patterns for *ATAD2* and *ATAD2B* were visualized using Gviz,⁶¹ and splice junctions with counts less than 5 were removed for sashimi plots.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We especially thank Brian E. Eckenroth in the Department of Microbiology and Molecular Genetics at the University of Vermont for his assistance with crystallographic data collection, processing, and analysis of the ATAD2B bromodomain structure in complex with C-38. We are very grateful to Dennis L. Buckley and James E. Bradner at the Dana-Farber Cancer Institute/Harvard Medical School in Boston, MA for resynthesizing and sharing compound 38 with us for use in this study. We also appreciate Kara McGuire's and Juliet Obi's assistance with the NMR chemical shift perturbation analysis and crystal growth, respectively, and Lauren Dunn's help with cloning the ATAD2B VDIEE short construct. This study was supported by the National Institutes of Health grants: R01GM129338 to K.C.G. and S.F., R44GM116584 and R44GM117683 to EpiCypher, and R15GM104865 to K.C.G. J.T.L. was the recipient of an ACPHS graduate research assistantship from 2016 to 2017. This study made use of the National Magnetic Resonance Facility at Madison, which is supported by NIH grant P41GM103399 (NIGMS). NMRFAM equipment was purchased with funds from the University of Wisconsin-Madison; the NIH P41GM103399, S10RR02781, S10RR08438, S10RR023438, S10RR025062, S10RR029220; the NSF DMB-8415048, OIA-9977486, BIR-9214394; and the USDA. Crystal growth, screening, and initial data collection were carried out at the Center for X-ray Crystallography at the University of Vermont, which is supported by the National Institutes of Health grants P01CA098993 and R01CA52040, awarded to Sylvie Doublié by the National Cancer Institute. GM/CA@APS has been funded in whole or in part with Federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract no. DE-AC02-06CH11357. We also thank Dr. Matthew Liptak and Amanda Roffman in the Department of Chemistry at the

University of Vermont for their advice and assistance in setting up circular dichroism spectroscopy experiments. The histone peptides and inhibitor compound used in this study were characterized by mass spectrometry by the supplying company/institution or by the Vermont Biomedical Research Network Proteomics Facility at the University of Vermont, which is supported by NIH grant P20GM103449 (NIGMS). DNA sequencing was performed at the Vermont Integrative Genomics Resource DNA Facility and was supported by University of Vermont Cancer Center, Lake Champlain Cancer Research Organization, and the UVM Larner College of Medicine.

ABBREVIATIONS

ATAD2	ATPase family AAA+ domain-containing 2
ATAD2B	ATPase family AAA+ domain-containing 2B
BRD	bromodomain
BRPF1/3	bromodomain and PHD finger-containing protein 1/3
CD	circular dichroism
GST	glutathione-S-transferase
HSQC	heteronuclear single quantum coherence
ITC	isothermal titration calorimetry
NMR	nuclear magnetic resonance
PHD	plant homeodomain
PTMs	post-translational modifications

REFERENCES

- (1). Hebbes TR; Thorne AW; Crane-Robinson C A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J 1988, 7, 1395–1402. [PubMed: 3409869]
- (2). Luger K; Richmond TJ The histone tails of the nucleosome. Curr. Opin. Genet. Dev 1998, 8, 140– 146. [PubMed: 9610403]
- (3). Norton VG; Imai BS; Yau P; Bradbury EM Histone acetylation reduces nucleosome core particle linking number change. Cell 1989, 57, 449–457. [PubMed: 2541913]
- (4). Li Y; Li Z; Dong L; Tang M; Zhang P; Zhang C; Cao Z; Zhu Q; Chen Y; Wang H; Wang T; Lv D; Wang L; Zhao Y; Yang Y; Wang H; Zhang H; Roeder RG; Zhu WG Histone H1 acetylation at lysine 85 regulates chromatin condensation and genome stability upon DNA damage. Nucleic Acids Res 2018, 46, 7716–7730. [PubMed: 29982688]
- (5). Banerjee DR; Deckard CE 3rd; Zeng Y; Sczepanski JT Acetylation of the histone H3 tail domain regulates base excision repair on higher-order chromatin structures. Sci. Rep 2019, 9, No. 15972.
- (6). Dey A; Ellenberg J; Farina A; Coleman AE; Maruyama T; Sciortino S; Lippincott-Schwartz J; Ozato K A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)to-M transition. Mol. Cell. Biol 2000, 20, 6537–6549. [PubMed: 10938129]
- (7). Filippakopoulos P; Picaud S; Mangos M; Keates T; Lambert JP; Barsyte-Lovejoy D; Felletar I; Volkmer R; Muller S; Pawson T; Gingras AC; Arrowsmith CH; Knapp S Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149, 214–231. [PubMed: 22464331]
- (8). Zeng L; Yap KL; Ivanov AV; Wang X; Mujtaba S; Plotnikova O; Rauscher FJ 3rd; Zhou MM Structural insights into human KAP1 PHD finger-bromodomain and its role in gene silencing. Nat. Struct. Mol. Biol 2008, 15, 626–633. [PubMed: 18488044]

- (9). VanDemark AP; Kasten MM; Ferris E; Heroux A; Hill CP; Cairns BR Autoregulation of the rsc4 tandem bromodomain by gcn5 acetylation. Mol. Cell 2007, 27, 817–828. [PubMed: 17803945]
- (10). Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications. Structure 2015, 23, 1801–1814. [PubMed: 26365797]
- (11). Lloyd JT; Glass KC Biological function and histone recognition of family IV bromodomaincontaining proteins. J. Cell. Physiol 2018, 233, 1877–1886. [PubMed: 28500727]
- (12). Leachman NT; Brellier F; Ferralli J; Chiquet-Ehrismann R; Tucker RP ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev., Growth Differ 2010, 52, 747–755. [PubMed: 21158754]
- (13). Snider J; Thibault G; Houry WA The AAA+ superfamily of functionally diverse proteins. Genome Biol 2008, 9, No. 216.
- (14). Poncet-Montange G; Zhan Y; Bardenhagen JP; Petrocchi A; Leo E; Shi X; Lee G. R. t.; Leonard PG; Geck Do MK; Cardozo MG; Andersen JN; Palmer WS; Jones P; Ladbury JE Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2. Biochem. J 2015, 466, 337–346. [PubMed: 25486442]
- (15). Morozumi Y; Boussouar F; Tan M; Chaikuad A; Jamshidikia M; Colak G; He H; Nie L; Petosa C; de Dieuleveult M; Curtet S; Vitte AL; Rabatel C; Debernardi A; Cosset FL; Verhoeyen E; Emadali A; Schweifer N; Gianni D; Gut M; Guardiola P; Rousseaux S; Gerard M; Knapp S; Zhao Y; Khochbin S Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells. J. Mol. Cell Biol 2016, 8, 349–362.
- (16). Koo SJ; Fernandez-Montalvan AE; Badock V; Ott CJ; Holton SJ; von Ahsen O; Toedling J; Vittori S; Bradner JE; Gorjanacz M ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication. Oncotarget 2016, 7, 70323–70335. [PubMed: 27612420]
- (17). Bamborough P; Chung CW; Furze RC; Grandi P; Michon AM; Sheppard RJ; Barnett H; Diallo H; Dixon DP; Douault C; Jones EJ; Karamshi B; Mitchell DJ; Prinjha RK; Rau C; Watson RJ; Werner T; Demont EH Structure-based optimization of naphthyridones into potent ATAD2 bromodomain inhibitors. J. Med. Chem 2015, 58, 6151–6178. [PubMed: 26230603]
- (18). Dhalluin C; Carlson JE; Zeng L; He C; Aggarwal AK; Zhou MM; Zhou MM Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399, 491–496. [PubMed: 10365964]
- (19). Mujtaba S; Zeng L; Zhou MM Structure and acetyl-lysine recognition of the bromodomain. Oncogene 2007, 26, 5521–5527. [PubMed: 17694091]
- (20). Ciro M; Prosperini E; Quarto M; Grazini U; Walfridsson J; McBlane F; Nucifero P; Pacchiana G; Capra M; Christensen J; Helin K ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 2009, 69, 8491–8498. [PubMed: 19843847]
- (21). Caron C; Lestrat C; Marsal S; Escoffier E; Curtet S; Virolle V; Barbry P; Debernardi A; Brambilla C; Brambilla E; Rousseaux S; Khochbin S Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 2010, 29, 5171–5181. [PubMed: 20581866]
- (22). Kalashnikova EV; Revenko AS; Gemo AT; Andrews NP; Tepper CG; Zou JX; Cardiff RD; Borowsky AD; Chen HW ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010, 70, 9402–9412. [PubMed: 20864510]
- (23). Wan WN; Zhang YX; Wang XM; Liu YJ; Zhang YQ; Que YH; Zhao WJ ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. Asian Pac. J. Cancer Prev 2014, 15, 2777–2783. [PubMed: 24761900]
- (24). Hwang HW; Ha SY; Bang H; Park CK ATAD2 as a poor prognostic marker for hepatocellular carcinoma after curative resection. Cancer Res. Treat 2015, 47, 853–861. [PubMed: 25687855]
- (25). Shang P; Meng F; Liu Y; Chen X Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis. Tumor Biol 2015, 36, 4479–4485.
- (26). Hou M; Huang R; Song Y; Feng D; Jiang Y; Liu M ATAD2 overexpression is associated with progression and prognosis in colorectal cancer. Jpn. J. Clin. Oncol 2016, 46, 222–227. [PubMed: 26819280]

- (27). Poplawski A; Hu K; Lee W; Natesan S; Peng D; Carlson S; Shi X; Balaz S; Markley JL; Glass KC Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. J. Mol. Biol 2014, 426, 1661–1676. [PubMed: 24333487]
- (28). Sobel RE; Cook RG; Perry CA; Annunziato AT; Allis CD Conservation of deposition-related acetylation sites in newly synthesized histones H3 and H4. Proc. Natl. Acad. Sci. U.S.A 1995, 92, 1237–1241. [PubMed: 7862667]
- (29). Goudarzi A; Zhang D; Huang H; Barral S; Kwon OK; Qi S; Tang Z; Buchou T; Vitte AL; He T; Cheng Z; Montellier E; Gaucher J; Curtet S; Debernardi A; Charbonnier G; Puthier D; Petosa C; Panne D; Rousseaux S; Roeder RG; Zhao Y; Khochbin S Dynamic competing histone H4 K5K8 acetylation and butyrylation are hallmarks of highly active gene promoters. Mol. Cell 2016, 62, 169–180. [PubMed: 27105113]
- (30). Zhang K; Williams KE; Huang L; Yau P; Siino JS; Bradbury EM; Jones PR; Minch MJ; Burlingame AL Histone acetylation and deacetylation: identification of acetylation and methylation sites of HeLa histone H4 by mass spectrometry. Mol. Cell. Proteomics 2002, 1, 500– 508. [PubMed: 12239278]
- (31). Thorne AW; Kmiciek D; Mitchelson K; Sautiere P; Crane-Robinson C Patterns of histone acetylation. Eur. J. Biochem 1990, 193, 701–713. [PubMed: 2249688]
- (32). Sasaki K; Ito T; Nishino N; Khochbin S; Yoshida M Real-time imaging of histone H4 hyperacetylation in living cells. Proc. Natl. Acad. Sci. U.S.A 2009, 106, 16257–16262. [PubMed: 19805290]
- (33). Shukla V; Vaissiere T; Herceg Z Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat. Res., Fundam. Mol. Mech. Mutagen 2008, 637, 1–15.
- (34). Leroy G; Dimaggio PA; Chan EY; Zee BM; Blanco MA; Bryant B; Flaniken IZ; Liu S; Kang Y; Trojer P; Garcia BA A quantitative atlas of histone modification signatures from human cancer cells. Epigenet. Chromatin 2013, 6, No. 20.
- (35). Langini C; Caflisch A; Vitalis A The ATAD2 bromodomain binds different acetylation marks on the histone H4 in similar fuzzy complexes. J. Biol. Chem 2017, 292, 16734–16745. [PubMed: 28798233]
- (36). Olp MD; Zhu N; Smith BC Metabolically derived lysine acylations and neighboring modifications tune the binding of the BET bromodomains to histone H4. Biochemistry 2017, 56, 5485–5495. [PubMed: 28945351]
- (37). Morinière J; Rousseaux S; Steuerwald U; Soler-Lopez M; Curtet S; Vitte AL; Govin J; Gaucher J; Sadoul K; Hart DJ; Krijgsveld J; Khochbin S; Muller CW; Petosa C Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009, 461, 664–668. [PubMed: 19794495]
- (38). Barretina J; Caponigro G; Stransky N; Venkatesan K; Margolin AA; Kim S; Wilson CJ; Lehar J; Kryukov GV; Sonkin D; Reddy A; Liu M; Murray L; Berger MF; Monahan JE; Morais P; Meltzer J; Korejwa A; Jane-Valbuena J; Mapa FA; Thibault J; Bric-Furlong E; Raman P; Shipway A; Engels IH; Cheng J; Yu GK; Yu J; Aspesi P Jr.; de Silva M; Jagtap K; Jones MD; Wang L; Hatton C; Palescandolo E; Gupta S; Mahan S; Sougnez C; Onofrio RC; Liefeld T; MacConaill L; Winckler W; Reich M; Li N; Mesirov JP; Gabriel SB; Getz G; Ardlie K; Chan V; Myer VE; Weber BL; Porter J; Warmuth M; Finan P; Harris JL; Meyerson M; Golub TR; Morrissey MP; Sellers WR; Schlegel R; Garraway LA The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483, 603–607. [PubMed: 22460905]
- (39). Meier JC; Tallant C; Fedorov O; Witwicka H; Hwang SY; van Stiphout RG; Lambert JP; Rogers C; Yapp C; Gerstenberger BS; Fedele V; Savitsky P; Heidenreich D; Daniels DL; Owen DR; Fish PV; Igoe NM; Bayle ED; Haendler B; Oppermann UCT; Buffa F; Brennan PE; Muller S; Gingras AC; Odgren PR; Birnbaum MJ; Knapp S Selective targeting of bromodomains of the bromodomain-PHD fingers family impairs osteoclast differentiation. ACS Chem. Biol 2017, 12, 2619–2630. [PubMed: 28849908]
- (40). Kwon SY; Xiao H; Wu C; Badenhorst P Alternative splicing of NURF301 generates distinct NURF chromatin remodeling complexes with altered modified histone binding specificities. PLoS Genet 2009, 5, No. e1000574.

- (41). Shigeno K; Yoshida H; Pan L; Luo JM; Fujisawa S; Naito K; Nakamura S; Shinjo K; Takeshita A; Ohno R; Ohnishi K Disease-related potential of mutations in transcriptional cofactors CREBbinding protein and p300 in leukemias. Cancer Lett 2004, 213, 11–20. [PubMed: 15312679]
- (42). Fernández-Montalván AE; Berger M; Kuropka B; Koo SJ; Badock V; Weiske J; Puetter V; Holton SJ; Stockigt D; Ter Laak A; Centrella PA; Clark MA; Dumelin CE; Sigel EA; Soutter HH; Troast DM; Zhang Y; Cuozzo JW; Keefe AD; Roche D; Rodeschini V; Chaikuad A; Diaz-Saez L; Bennett JM; Fedorov O; Huber KVM; Hubner J; Weinmann H; Hartung IV; Gorjanacz M Isoform-selective ATAD2 chemical robe with novel chemical structure and unusual mode of action. ACS Chem. Biol 2017, 12, 2730–2736. [PubMed: 29043777]
- (43). Champagne KS; Piscitelli E; Francklyn CS Substrate recognition by the hetero-octameric ATP phosphoribosyltransferase from Lactococcus lactis. Biochemistry 2006, 45, 14933–14943. [PubMed: 17154531]
- (44). Jain K; Fraser CS; Marunde MR; Parker MM; Sagum C; Burg JM; Hall N; Popova IK; Rodriguez KL; Vaidya A; Krajewski K; Keogh MC; Bedford MT; Strahl BD Characterization of the plant homeodomain (PHD) reader family for their histone tail interactions. Epigenet. Chromatin 2020, 13, No. 3.
- (45). Weinberg DN; Papillon-Cavanagh S; Chen H; Yue Y; Chen X; Rajagopalan KN; Horth C; McGuire JT; Xu X; Nikbakht H; Lemiesz AE; Marchione DM; Marunde MR; Meiners MJ; Cheek MA; Keogh MC; Bareke E; Djedid A; Harutyunyan AS; Jabado N; Garcia BA; Li H; Allis CD; Majewski J; Lu C The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. Nature 2019, 573, 281–286. [PubMed: 31485078]
- (46). Williamson MP Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc 2013, 73, 1–16. [PubMed: 23962882]
- (47). Lee W; Bahrami A; Markley JL ADAPT-NMR Enhancer: complete package for reduced dimensionality in protein NMR spectroscopy. Bioinformatics 2013, 29, 515–517. [PubMed: 23220573]
- (48). Lee W; Hu K; Tonelli M; Bahrami A; Neuhardt E; Glass KC; Markley JL Fast automated protein NMR data collection and assignment by ADAPT-NMR on Bruker spectrometers. J. Magn. Reson 2013, 236, 83–88. [PubMed: 24091140]
- (49). Lee W; Westler WM; Bahrami A; Eghbalnia HR; Markley JL PINE-SPARKY: graphical interface for evaluating automated probabilistic peak assignments in protein NMR spectroscopy. Bioinformatics 2009, 25, 2085–2087. [PubMed: 19497931]
- (50). Goddard TD; Kneller DG Sparky3; University of California: San Francisco.
- (51). Lee W; Tonelli M; Markley JL NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 2015, 31, 1325–1327. [PubMed: 25505092]
- (52). Louis-Jeune C; Andrade-Navarro MA; Perez-Iratxeta C Prediction of protein secondary structure from circular dichroism using theoretically derived spectra. Proteins 2012, 80, 374–381. [PubMed: 22095872]
- (53). Farley C; Juers DH Efficient cryoprotection of macro-molecular crystals using vapor diffusion of volatile alcohols. J. Struct. Biol 2014, 188, 102–106. [PubMed: 25286441]
- (54). McCoy AJ; Grosse-Kunstleve RW; Adams PD; Winn MD; Storoni LC; Read RJ Phaser crystallographic software. J. Appl. Crystallogr 2007, 40, 658–674. [PubMed: 19461840]
- (55). Emsley P; Cowtan K Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr 2004, 60, 2126–2132. [PubMed: 15572765]
- (56). Adams PD; Afonine PV; Bunkoczi G; Chen VB; Davis IW; Echols N; Headd JJ; Hung LW; Kapral GJ; Grosse-Kunstleve RW; McCoy AJ; Moriarty NW; Oeffner R; Read RJ; Richardson DC; Richardson JS; Terwilliger TC; Zwart PH PHENIX: a comprehensive Python-based system for macro-molecular structure solution. Acta Crystallogr., Sect. D: Biol. Crystallogr 2010, 66, 213–221. [PubMed: 20124702]
- (57). Davis IW; Leaver-Fay A; Chen VB; Block JN; Kapral GJ; Wang X; Murray LW; Arendall WB 3rd; Snoeyink J; Richardson JS; Richardson DC MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007, 35, W375–W383. [PubMed: 17452350]

- (58). Urzhumtseva L; Afonine PV; Adams PD; Urzhumtsev A Crystallographic model quality at a glance. Acta Crystallogr., Sect. D: Biol. Crystallogr 2009, 65, 297–300. [PubMed: 19237753]
- (59). Barretina J; Caponigro G; Stransky N; Venkatesan K; Margolin AA; Kim S; Wilson CJ; Lehar J; Kryukov GV; Sonkin D; Reddy A; Liu M; Murray L; Berger MF; Monahan JE; Morais P; Meltzer J; Korejwa A; Jane-Valbuena J; Mapa FA; Thibault J; Bric-Furlong E; Raman P; Shipway A; Engels IH; Cheng J; Yu GK; Yu J; Aspesi P Jr.; de Silva M; Jagtap K; Jones MD; Wang L; Hatton C; Palescandolo E; Gupta S; Mahan S; Sougnez C; Onofrio RC; Liefeld T; MacConaill L; Winckler W; Reich M; Li N; Mesirov JP; Gabriel SB; Getz G; Ardlie K; Chan V; Myer VE; Weber BL; Porter J; Warmuth M; Finan P; Harris JL; Meyerson M; Golub TR; Morrissey MP; Sellers WR; Schlegel R; Garraway LA The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483, 603–607. [PubMed: 22460905]
- (60). Boyd J Seqsetvis: Set Based Visualizations for Next-Gen Sequencing Data, R package version 1.6.0, 2019.
- (61). Hahne F; Ivanek R Visualizing Genomic Data Using Gviz and Bioconductor In Statistical Genomics; Mathé E; Davis S, Eds.; Methods in Molecular Biology; Humana Press, 2016; Vol. 1418, pp 335–351.

Lloyd et al.

Page 24




Figure 1.

ATAD2B bromodomain recognizes acetylated histones. (A) Heat map represents the relative binding of GST-tagged ATAD2 and ATAD2B bromodomains to histone peptides using AlphaScreen technology (i.e., dCypher phase B: see the Methods section). *a* counts (n = 2) were normalized for each protein to the highest fluorescent intensity signal for each respective assay, and the relative binding strength is indicated by the color gradient. (B) Pie charts for ATAD2/B bromodomains indicate the number of peptides classified as positive binders (*a* counts having signals >5000, which is at least twice that of the relevant unmodified control peptide) (full dCypher peptide screen data in Tables S1 and S2, and Resources Table A). (C) Exothermic ITC enthalpy plots for the binding of the ATAD2B bromodomain to mono- and diacetylated histone ligands. The calculated binding constants are indicated.




Figure 2.

Mapping of the mono- and diacetylated histone ligand binding interfaces on the ATAD2B bromodomain. (A) Histogram shows the normalized ${}^{1}\text{H}{-}{}^{15}\text{N}$ chemical shift changes observed in the backbone amides of the ATAD2B bromodomain upon the addition of peptides H4K5ac (1–10) (green), H4K5acK8ac (1–10) (purple), H4K5ac (1–15) (blue), and H4K5acK12ac (1–15) (red) in a 1:5 (protein/peptide) molar ratio. The secondary structure elements for the bromodomain are represented above the histogram. A cylinder indicates an *a*-helical structure, and a straight line depicts loop regions. (B) Chemical shift perturbations mapped onto the solvent-accessible surface representation of the apo ATAD2B

bromodomain (PDB ID: 3LXJ) with the addition of H4K5ac (1–10), H4K5acK8ac (1–10), H4K5ac (1–15), and H4K5acK12ac (1–15). CSPs that are 0.5, 1, and 2 standard deviations from the average shift changes are colored in yellow, orange, and red, respectively. (C) Cartoon representation of the ATAD2B bromodomain with the ZA loop region (residues 977–1004) colored in green and the extended region around the BC loop (residues 1031–1055) involved in chemical shift perturbations in magenta. The seven amino acid residues exhibiting the largest chemical shift changes are labeled in stick representation.

Lloyd et al.




Figure 3.

Analysis of targeted mutations and noncanonical splice variants in the ATAD2B bromodomain. (A) RNA-seq and sashimi plots showing expression and splice junctions across the ATAD2B gene. Normalized expression values are on the y-axis. The highlighted region indicates exons 20-22 that encode the ATAD2B bromodomain. The junctions for these exons are shown on the right where the number of reads spanning each junction is shown, and the noncanonical splice variant is in red. (B) Reverse transcription-polymerase chain reaction (RT-PCR) and Sanger sequencing showing both ATAD2B and ATAD2B_{short} isoforms. The amino acids excluded from ATAD2B_{short} as a result of alternative 5' splice donor sites are highlighted in red. (C) Surface representation of the apo ATAD2B bromodomain (PDB ID: 3LXJ) showing the location of specific point mutations introduced to the binding pocket by site-directed mutagenesis and the location of the residues excluded from the ATAD2B_{short} splice variant. (D) Circular dichroism spectra in the far-UV region of the ATAD2B, ATAD2B mutant, and ATAD2B_{short} bromodomains. The percent *a*-helical content for each protein is listed in the inset. (E) Thermal stability assay showing the ATAD2B bromodomain unfolding curve (blue) with a $T_{\rm m} = 48$ °C, while the ATAD2B_{short} bromodomain (orange) demonstrated a significantly lower $T_{\rm m} = 41$ °C.

Lloyd et al.




Figure 4.

Coordination of bromodomain inhibitor molecules by the ATAD2 and ATAD2B bromodomains. (A) ATAD2B bromodomain in complex with compound 38 (PDB ID: 6VEO). (B) ATAD2 bromodomain in complex with compound 42. Hydrogen bonds are indicated by a red dashed line. (C) Simulated annealing composite omits map (gray) representing the bound compound 38 (green) in complex with the ATAD2B bromodomain (cyan) contoured at 1σ . (D) Isolated image of the simulated annealing composite omits map (gray) around compound 38 (green) contoured at 1σ . The simulated annealing composite omits maps shown in (C) and (D) were calculated prior to building the ligand into the structure. Figures were generated with the PyMOL Molecular Graphics System, version 2.3, Schrödinger, LLC.

Table 1.

Binding Affinities of the ATAD2B Bromodomain to Acetylated Histone Ligand Measured by ITC

histone peptide	sequence	ATAD2B ITC $K_{\rm D}$ (μ M)	ATAD2 reported K _{Ds}
H2AK5ac (res 1–12) ^a	SGRG(Kac)QGGKARA	42.5 ± 2.9	q NV
H4 unmodified (res $4-17)^{a}$	GKGGKGLGKGGAKRHRK	no binding	NA
H4K5ac (res $1-15)^{a}$	SGRG(Kac)GGKGLGKGGA	5.2 ± 1.0	NA
H4K5ac (res $1-10)^{a}$	SGRG(Kac)GGKGL	48.0 ± 4.7	22 μ M (res 1–20) ¹⁴
H4K5ac (res $4-17$) ^{a}	G(Kac)GGKGLGKGGAKR	no binding	NA
H4K8ac (res $1-10)^{a}$	SGRGKGG(Kac)GL	1164.2 ± 28.5	NA, interaction shown ¹⁶
H4K8ac (res 4–17)	GKGG(Kac)GLGKGGAKR	no binding	NA
H4K12ac (res 4–17) ^a	GKGGKGLG(Kac)GGAKR	50.5 ± 5.8	2.5 µM (res 1–25) ¹⁶
H4K12ac (res 1–15)	SGRGKGGKGLG(Kac)GGA	685.3 ± 91.7	NA
H4K16ac (res 10–20) ^a	LGKGGA(Kac)RHRK	no binding	NA
H4K5acK8ac (res 1–10) ^a	SGRG(Kac)GG(Kac)GL	28.1 ± 1.6	NA
H4K5acK12ac (res 1–15) ^a	SGRG(Kac)GGKGLG(Kac)GGA	18.7 ± 0.9	NA, interaction shown ¹⁶
H4K5acK16ac (1–24)	SGRG(Kac)GGKGLGKGGA(Kac)RHRKVLRD	34.4 ± 6.2	NA
H4K8acK12ac (res 6–15)	GG(Kac)GLG(Kac)GGA	no binding	NA
H4K8acK16ac (1-20)	SGRGKGG(Kac)GLGKGGA(Kac)RHRK	35.7 ± 6.5	NA
H4K12acK16ac (res 10-20)	LG(Kac)GGA(Kac)RHRK	213.9 ± 7.0	NA
H3 unmodified (res $1-12)^{a}$	ARTKQTARKSTG	no binding	NA
H3K9ac (res 1-12)	ARTKQTAR(Kac)STG	no binding	NA
H3K14ac (res 8–19) ^{<i>a</i>}	RKSTGG(Kac)APRKQ	no binding	no binding (res 1–21) ¹⁴
compound 38		$166.9\pm5.6~\mathrm{nM}$	90 nM^{17}

J Med Chem. Author manuscript; available in PMC 2021 February 16.

 b NA indicates that the information was "not available" in the literature for the ATAD2 bromodomain.

-
₽
~
_
—
_
~
0
\simeq
_
-
\leq
≤a
Mar
Man
Manu
Manu
Manus
SC
S
SC
SC

Author Manuscript

ATAD2B bromodomain	H2AK5ac (1–12)	H4K5ac (1-10)	H4K12ac (4–17)	H4K5acK8ac (1-10)	H4K5acK12ac (1-15)	ATAD2B bromodomain H2AK5ac (1–12) H4K5ac (1–10) H4K12ac (4–17) H4K5acK8ac (1–10) H4K5acK12ac (1–15) H4 unmodified (4–17) compound 38	compound 38
ATAD2B			50.5 ± 5.8	28.1 ± 1.6	18.7 ± 0.9	no binding	$166.9 \pm 5.6 \text{ nM}$
V1038A			no binding	622.8 ± 38.5	411.7 ± 39.1	no binding	
Y995A	no binding	no binding	no binding	no binding	no binding	no binding	
71037A	no binding	no binding	no binding	no binding	no binding	no binding	
ATAD2B _{short}	no binding	no binding	no binding	no binding	no binding	no binding	no binding

Dissociation values are micromolar (μ M) unless otherwise noted.

Table 3.

Analysis of the ATAD2B Bromodomain Wild-Type and Mutant Proteins by Circular Dichroism Spectroscopy

ATAD2B bromodomain	% <i>a</i> -helix	%β-strand
WT	91.36	0.46
N1038A	91.38	0.50
Y995A	91.39	0.49
Y1037A	91.39	0.49
ATAD2B _{short}	91.37	0.18

Table 4.

Summary of the Data Collection and Refinement Statistics for the ATAD2B Bromodomain in Complex with C-38

(collection on a single crystal) PDB code	ATAD2B/compound 38 6VEO
data collection	
space group	<i>P</i> 6 ₁ 22
cell dimensions	
<i>a, b, c</i> (Å)	76.358, 76.358, 102.312
a, β, γ (deg)	90, 90, 120
resolution (Å)	19.55–2.4 (2.486–2.4 ^{<i>a</i>})
R-pim (%)	1.997 (17.07)
CC _{1/2}	1 (0.909)
mean $I \sigma(I)$	21.51 (3.95)
completeness (%)	99.61 (100.0)
redundancy	2.0 (2.0)
refinement	
resolution (Å)	19.55–2.4
no. unique reflections	7332 (709)
$R_{\rm work}/R_{\rm free}$	19.29/25.48
no. atoms	
protein	1138
ligand/ion	46
waters	100
average <i>B</i> -factors (Å ²)	
protein	43.9
ligands/ions	51.9
water	47.8
R.M.S. deviations	
bond lengths (Å)	0.005
bond angles (deg)	0.55
Ramachandran plot (%)	
favored	97.76
alowed	2.24
outliers	0
clash score	2.98

 a Highest resolution shell is shown in parentheses.